<DOC>
	<DOCNO>NCT00948389</DOCNO>
	<brief_summary>To determine whether dasatinib plus lomustine effective treatment recurrent glioblastoma</brief_summary>
	<brief_title>Study CCNU ( Lomustine ) Plus Dasatinib Recurrent Glioblastoma ( GBM )</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Lomustine</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Patients histological cytological proven glioblastoma multiforme Recurrent progressive disease document magnetic resonance imaging ( MRI ) World Health Organization ( WHO ) Performance status 0 2 Patient may operate recurrence For non operate patient , recurrent disease must least one bidimensionally measurable target lesion one diameter least 2cm Patients must stable decrease dose corticosteroid least 1 week prior baseline MRI Patients histological cytological proven glioblastoma multiforme Completion radiotherapy brain le 3 month prior registration/randomization Prior treatment high dose radiotherapy , stereotactic radiosurgery internal radiation therapy Previous current malignancy site within prior 3 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>